cetpinhibition.org

Genetics

CETP TaqIB B2 allele is less common in African Americans than Caucasians, ruling it out as an explanation for higher HDL-C (Atherosclerosis 2002)

Original title: The frequency of the cholesteryl ester transfer protein-TaqI B2 allele is lower in African Americans than in Caucasians

Atherosclerosis · · 6

Cuchel M, Wolfe ML, deLemos AS, Rader DJ

To test whether higher HDL-cholesterol in African Americans could be explained by a higher frequency of the HDL-raising CETP TaqIB B2 allele, researchers genotyped 395 African Americans and 362 Caucasians across healthy-volunteer (NORM) and cardiac-catheterization (CATH) cohorts. Contrary to the hypothesis, B2 allele frequency was significantly lower in African Americans than Caucasians in both the NORM group (0.26 vs 0.44, P<0.001) and CATH group (0.28 vs 0.38, P=0.01). B2 carriers had higher HDL-cholesterol than B1B1 subjects in Caucasians (both cohorts) and in CATH-African Americans, but not in NORM-African Americans, and no other significant lipid associations were found. The results indicate the TaqIB B2 allele is less frequent, not more, in African Americans, making it an unlikely explanation for their higher HDL-C levels.

Read the paper (DOI)PubMed

Original abstract

Cholesteryl ester transfer protein (CETP) mediates the exchange of cholesteryl ester for triglyceride between high density lipoprotein (HDL) and very low density lipoprotein. The B2 allele of the TaqIB polymorphism located in the first intron of the CETP gene occurs with an allele frequency of about 0.40 in Caucasians and is associated with decreased CETP levels and activity and with higher HDL-cholesterol (HDL-C) levels in this racial group. We hypothesized that the higher levels of HDL-C seen in African Americans compared with Caucasians could be in part explained by a higher frequency of the TaqI B2 allele. We determined the distribution of this polymorphism in a total of 395 African Americans and 362 Caucasian ascertained as two independent cohorts: one of healthy volunteers (NORM) and the other of patients undergoing cardiac catheterization (CATH). Of the 244 NORM-African Americans studied, 56% were B1B1, 37% B1B2 and 7% B2B2, compared with the 224 NORM-Caucasians of which 33% were B1B1, 45% B1B2 and 22% B2B2. In the CATH-African American group (n=151) 51% were B1B1, 41% B1B2 and 8% B2B2 compared with 35% CATH-Caucasians B1B1, 54% B1B2 and 11% B2B2. The frequency of the B2 allele in the Caucasian subjects in both cohorts was similar to that reported in the literature. The frequency of the B2 allele was significantly lower in African Americans than in Caucasians in the NORM group (0.26 vs 0.44; chi(2)=36.5, P<0.001) and in the CATH group (0.28 vs 0.38, chi(2)=4.7, P=0.01). Carriers of the B2 allele had higher HDL-C levels compared with B1B1 subjects in Caucasians (NORM: 57 vs 53 mg/dl, P=0.035; CATH: 47 vs 42 mg/dl, P=0.049) and in CATH-African Americans (48 vs 43 mg/dl, P=0.028), but not in NORM-African Americans (55 vs 54 mg/dl, P=0.494). There were no other significant associations between this polymorphism and other lipids and lipoproteins in the subjects studied. These results suggest that, in contrast to our hypothesis, the B2 allele of the TaqIB polymorphism is less frequent in African Americans compared with Caucasians and that this polymorphism is unlikely to contribute to the higher levels of HDL-C reported in the African American population.

ancestrygenetics

Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.